Deepu Madduri, MD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSISTANT PROFESSOR | Urology
Deepu Madduri, MD is Assistant Professor of Medicine (Hematology and Medical Oncology). She is Associate Director, Cellular Therapy Service, and Director of Clinical Operations with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. Dr. Madduri specializes in plasma cell disorders including multiple myeloma, amyloid light-chain amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance. She performs a variety of procedures including bone marrow biopsies and stem cell transplant. She serves as the lead physician liaison between the Center of Excellence for Multiple Myeloma and the Bone Marrow and Stem Cell Transplantation Program at The Mount Sinai Hospital.
Dr. Madduri’s research focuses on the clinical management of plasma cell dyscrasias with a strong emphasis on relapsed and refractory multiple myeloma. Her research has included first-in-human/phase 1 clinical trial studies ranging from immunotherapy with checkpoint inhibitors and immune effector cells such as CAR T-cell therapy, NK-cell therapy, and Bi-specific antibodies. She has played an integral role in initiating CAR T-cell studies for myeloma. She is also a member of the Clinical Research Services team for cellular therapies at Mount Sinai and a member of the Bone Marrow Transplant Clinical Trials Network protocol committee.
Dr. Madduri received her MD from the College of Medicine at the University of Oklahoma. She completed her residency in Internal Medicine at St. Mary Medical Center in Langhorne, Pennsylvania, and a fellowship in Hematology and Oncology at the University of California, Harbor Campus in Torrance, California, with additional fellowship training in Blood and Marrow Transplant at Stanford Hospital. Dr. Madduri serves as an oncology consultant at Foundation Medicine, Inc., a cancer genomic company, and leads their Smart Trials Precision enrollment program.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Madduri during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Bristol-Myers Squibb
- Foundation Medicine, Inc.
- Janssen Research & Development, LLC
- Legend Biotech
- Takeda Pharmaceutical Company Limited
Scientific Advisory Board:
- Bristol-Myers Squibb
- Celgene Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.